Title: EU Extends Indication of Bosentan to Pulmonary Arterial Hypertension WHO FC II
|
|
To print: Select File and then Print from your browser's menu Title: EU Extends Indication of Bosentan to Pulmonary Arterial Hypertension WHO FC II |
|
"EU Extends Indication of Bosentan to Pulmonary Arterial Hypertension WHO FC II" NEW YORK -- August 6, 2008 -- The European Union (EU) has approved bosentan (Tracleer) for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH World Health Organization [WHO] functional class [FC] II). The approval is based on the results from the Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY). The randomised, double-blind, placebo-controlled study of 185 patients showed that pulmonary vascular resistance improved significantly, with a reduction of 22.6% ([P < .0001) after 6 months compared with placebo. A 77% risk reduction in time to clinical worsening (P = .011) was seen after 6 months compared with placebo. Patients receiving bosentan had a lower incidence of worsening functional class (3.4%) compared with placebo (13.2%). |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |